NIMBEX® (cisatracurium besylate)

grdientline
A Nondepolarizing Neuromuscular Blocking (NMB) Agent
nimbex-bottles

AN APPROPRIATE CHOICE FOR YOUR PATIENTS REQUIRING AN NMB1

  • Intermediate onset and duration of action
  • Recovery profile of NIMBEX is unchanged in the presence of renal or hepatic failure, which is consistent with predominantly organ-independent Hofmann elimination
  • AEs <1%: bradycardia, hypotension, flushing, bronchospasm, and/or rash
  • Clinical trial adverse events (AEs) were uncommon in surgical patients (N=945): No events reported > 1%
  • Severe anaphylactic reactions to NMBs, including NIMBEX, have been reported
  • Administer in carefully adjusted dosage by experienced clinicians in facilities with resuscitation/ life support capabilities